"Immunohistochemistry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
| Descriptor ID |
D007150
|
| MeSH Number(s) |
E01.370.225.500.607.512 E01.370.225.750.551.512 E05.200.500.607.512 E05.200.750.551.512 E05.478.583 H01.158.100.656.234.512 H01.158.201.344.512 H01.158.201.486.512 H01.181.122.573.512 H01.181.122.605.512
|
| Concept/Terms |
Immunolabeling Techniques- Immunolabeling Techniques
- Immunolabeling Technique
- Technique, Immunolabeling
- Techniques, Immunolabeling
- Immunolabeling Technics
- Immunolabeling Technic
- Technic, Immunolabeling
- Technics, Immunolabeling
Immunogold Techniques- Immunogold Techniques
- Immunogold Technique
- Technique, Immunogold
- Techniques, Immunogold
- Immunogold Technics
- Immunogold Technic
- Technic, Immunogold
- Technics, Immunogold
Immunogold-Silver Techniques- Immunogold-Silver Techniques
- Immunogold Silver Techniques
- Immunogold-Silver Technique
- Technique, Immunogold-Silver
- Techniques, Immunogold-Silver
- Immunogold-Silver Technics
- Immunogold Silver Technics
- Immunogold-Silver Technic
- Technic, Immunogold-Silver
- Technics, Immunogold-Silver
|
Below are MeSH descriptors whose meaning is more general than "Immunohistochemistry".
Below are MeSH descriptors whose meaning is more specific than "Immunohistochemistry".
This graph shows the total number of publications written about "Immunohistochemistry" by people in this website by year, and whether "Immunohistochemistry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 29 | 29 |
| 1997 | 2 | 36 | 38 |
| 1998 | 0 | 27 | 27 |
| 1999 | 0 | 36 | 36 |
| 2000 | 1 | 33 | 34 |
| 2001 | 0 | 47 | 47 |
| 2002 | 0 | 47 | 47 |
| 2003 | 0 | 55 | 55 |
| 2004 | 0 | 47 | 47 |
| 2005 | 0 | 64 | 64 |
| 2006 | 0 | 61 | 61 |
| 2007 | 0 | 56 | 56 |
| 2008 | 3 | 57 | 60 |
| 2009 | 0 | 69 | 69 |
| 2010 | 2 | 64 | 66 |
| 2011 | 2 | 50 | 52 |
| 2012 | 0 | 60 | 60 |
| 2013 | 1 | 57 | 58 |
| 2014 | 3 | 52 | 55 |
| 2015 | 2 | 43 | 45 |
| 2016 | 2 | 45 | 47 |
| 2017 | 4 | 39 | 43 |
| 2018 | 1 | 30 | 31 |
| 2019 | 4 | 28 | 32 |
| 2020 | 5 | 17 | 22 |
| 2021 | 1 | 22 | 23 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 4 | 5 |
| 2024 | 1 | 17 | 18 |
| 2025 | 3 | 5 | 8 |
| 2026 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunohistochemistry" by people in Profiles.
-
A "Double-Hit" Lymphoma With Plasmablastic Features and Aberrant Keratin Expression Likely Transforming From Follicular Lymphoma. Int J Surg Pathol. 2026 Dec; 34(8):2125-2131.
-
Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors. Hum Pathol. 2026 Sep; 175:106154.
-
Comprehensive analysis of six MED15::TFE3 renal cell carcinomas including two novel solid MED15::TFE3 renal cell carcinomas, highlighting their morphologic, immunohistochemical and molecular differences from their cystic counterparts. Virchows Arch. 2026 Sep; 489(3):669-680.
-
Utilization of Key Morphologic and Molecular Prognostic and Predictive Parameters in Endometrial Malignancies: A Survey of Gynecologic Pathologists. Int J Surg Pathol. 2026 Aug; 34(5):1134-1145.
-
Current Trends in Melanocytic Lesions. Dermatol Clin. 2026 Apr; 44(2):183-190.
-
PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases. Histopathology. 2026 Jun; 88(7):1315-1323.
-
Mammary-type Metaplastic Carcinoma Arising From Vulvar Hidradenoma Papilliferum: A Case Report. Int J Gynecol Pathol. 2026 Nov 01; 45(6):490-494.
-
Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease. Clin Transl Sci. 2025 12; 18(12):e70422.
-
MTOR-mutated eosinophilic renal cell carcinomas with loss of chromosome 1 and high metastatic potential: further expanding the spectrum of TSC/mTOR pathway mutated renal tumors. Virchows Arch. 2026 Sep; 489(3):575-581.
-
Spatial heterogeneity of FGFR2b in gastric cancer: a comparative analysis of primary tumors and peritoneal dissemination. Virchows Arch. 2026 Jun; 488(6):1275-1282.